和誉-B:ABSK021的TGCTIII期结果优秀 ABSK011将启动HCCIII期临床事件

天风证券
14 Mar

事件近日公司发布2024 年度业绩公告:2024 年全年总收入5.04 亿元,同比增长2544%,主要是因为收到了来自Merck 的7 千万美元首付款;2024 年净利润为2830 万元,同比增长107%。ABSK021 的TGCT III 期临床疗效优秀,GvHD 的20mg 剂量组未来可期ABSK021 的TGCT 适应症III 期疗效安全性双优。2024 年11 月,ABSK021(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10